Innate Pharma highlights next generation of cancer immunotherapies at the American Association of Cancer Research (AACR) 2019 annual meeting
2018 financial results and business update: landmark deal with AstraZeneca to support transition into a fully integrated oncology-focused biotech, strong clinical progress in lead assets
Innate Pharma announces the appointment of Jennifer Butler as Executive Vice President, General Manager, US
Innate Pharma announces appointment of Laure-Hélène Mercier to the Executive Board
Innate Pharma receives FDA fast track designation for IPH4102 in relapsed or refractory Sézary syndrome
Innate Pharma announces its financial calendar for 2019
Upcoming investor conferences
Innate Pharma announces updated results that support advancement of IPH4102 in refractory Sézary syndrome at the American Society of Hematology (ASH) 2018 annual meeting
Innate Pharma announces publication of monalizumab research in the prestigious “Cell” journal widening the horizon of immune checkpoint inhibitors
Innate Pharma appoints experts to new Strategic Advisory Board
